|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||0.0484 - 0.0484|
|52 Week Range||0.0450 - 0.9020|
|Beta (5Y Monthly)||0.89|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 11, 2022 - Aug 15, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||0.50|
Subscribe to Yahoo Finance Plus to view Fair Value for APLIF
HALIFAX, Nova Scotia, August 02, 2022--Appili Therapeutics Inc. (TSX:APLI; OTCQX: APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced that Armand Balboni, M.D, Ph.D, Chief Executive Officer, and Yoav Golan, M.D, Chief Medical Officer of Appili, will participate at the seventh iteration of WorldLeish, from August 1 to 6 2022, and present an update on Appili program ATI-1801.
Bautz: By David Bautz, PhD OTC:APLIF | TSX:APLI.TO READ THE FULL APLIF RESEARCH REPORT Business Update New Late-Stage Program in Cutaneous Leishmaniasis On April 13, 2022, Appili Therapeutics Inc. (OTC:APLIF) (TSX:APLI.TO) announced the addition of ATI-1801, a late stage clinical program to treat cutaneous leishmaniasis. The product, a topical formulation of paromomycin, was licensed from the
HALIFAX, Nova Scotia, June 29, 2022--Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced its financial and operational results for the fiscal year ended March 31, 2022, and provided an update on the Company’s strategy for fiscal 2023. All figures are stated in Canadian dollars unless otherwise stated.